QOL Medical to acquire Evoke.

QOL Medical, a biopharmaceutical company specializing in treatments for GI and rare diseases, agreed to acquire Evoke, a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. Financial terms are not disclosed. “We are excited about the strategic alignment between QOL and Evoke. Evoke has developed an innovative therapy that addresses a significant unmet need in gastrointestinal care, offering meaningful clinical benefits for patients. GIMOTI strengthens our GI portfolio and advances our mission to support patients living with rare and underserved gastrointestinal conditions," Derick Cooper, QOL Medical CEO.